AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating restated by equities research analysts at Shore Capital in a report released on Wednesday.
Several other analysts also recently commented on the stock. Deutsche Bank AG reaffirmed a “buy” rating and issued a GBX 5,800 ($75.71) price objective on shares of AstraZeneca plc in a report on Wednesday. Citigroup Inc. reaffirmed a “buy” rating on shares of AstraZeneca plc in a report on Friday, September 23rd. Jefferies Group reaffirmed a “buy” rating and issued a GBX 5,800 ($75.71) price objective on shares of AstraZeneca plc in a report on Wednesday, September 21st. Societe Generale reaffirmed a “buy” rating and issued a GBX 7,000 ($91.37) price objective on shares of AstraZeneca plc in a report on Wednesday, September 14th. Finally, BNP Paribas downgraded shares of AstraZeneca plc to a “neutral” rating and set a GBX 5,200 ($67.88) price objective on the stock. in a report on Wednesday, September 14th. Five analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. AstraZeneca plc presently has a consensus rating of “Hold” and an average target price of GBX 4,926.80 ($64.31).
Shares of AstraZeneca plc (LON:AZN) opened at 4969.00 on Wednesday. The stock’s market capitalization is GBX 62.86 billion. The stock’s 50 day moving average is GBX 5,019.33 and its 200-day moving average is GBX 4,394.52. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00.
The company also recently declared a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were paid a GBX 68.70 ($0.90) dividend. The ex-dividend date of this dividend was Thursday, August 11th. This represents a yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.